Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab

Journal of Clinical Oncology

Volumn 28, Issue 6, 2010, Pages

  Gerstner, Elizabeth R ^a   Frosch, Matthew P ^a   Batchelor, Tracy T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; IRINOTECAN; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BRAIN VENTRICLE; CANCER DIAGNOSIS; CANCER INFILTRATION; CASE REPORT; DIFFUSION WEIGHTED IMAGING; DRUG WITHDRAWAL; GLIOBLASTOMA; HUMAN; MALE; PRIORITY JOURNAL; SALVAGE THERAPY; STEREOTACTIC BIOPSY; TUMOR GROWTH; BRAIN TUMOR; PATHOLOGY; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; DIFFUSION MAGNETIC RESONANCE IMAGING; GLIOBLASTOMA; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; YOUNG ADULT;

EID: 77949911509     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.0233     Document Type: Article

References (11)

1. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007 (Pubitemid 46075199)
2. Cloughesy TF, Prados MD, Wen PY, et al: A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26:91s, 2008 (abstr 2010b)
3. Vredenburgh JJ, Desjardins A, Herndon Jr JE, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259, 2007 (Pubitemid 46424067)
4. Kunkel P, Ulbricht U, Bohlen P, et al: Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624-6628, 2001 (Pubitemid 32896475)
5. Rubenstein JL, Kim J, Ozawa T, et al: Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306-314, 2000
6. Kamoun WS, Ley CD, Farrar CT, et al: Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27:2542-2552, 2009
7. Thoeny HC, De Keyzer F, Chen F, et al: Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 234:756-764, 2005 (Pubitemid 40250819)
8. Lee KC, Hall DE, Hoff BA, et al: Dynamic imaging of emerging resistance during cancer therapy. Cancer Res 66:4687-4692, 2006
9. Hamstra DA, Galban CJ, Meyer CR, et al: Functional diffusion map as an early imaging biomarker for high-grade glioma: Correlation with conventional radiologic response and overall survival. J Clin Oncol 26:3387-3394, 2008
10. Gerstner ER, Chen P-J, Wen PY, et al: Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro-Oncology (in press)
11. Akter M, Hirai T, Makino K, et al: Diffusion-weighted imaging of primary brain lymphomas: Effect of ADC value and signal intensity of T2-weighted imaging. Comput Med Imaging Graph 32:539-543, 2008